Virtuoso Therapeutics to Present Preclinical Findings on Two Best-in-Class Bispecific Programs at the 2022 American Association for Cancer Research (AACR) Annual Meeting
Multiple Modes of Action of the CD38 x ICAM-1 Bispecific AntibodyAACR • April 8-13, 2022; New Orleans, LA
VBI-002, a CD47 x ICAM-1 Bispecific Antibody Represents a Novel Approach for Treating ICAM-1 Overexpressing TumorsAACR • April 8-13, 2022; New Orleans, LA
CD47 x EpCAM Bispecific Antibody Represents a Novel Approach for Treating EpCAM Overexpressing Solid Tumor SITC • November 10-14, 2021; Washington, D.C.
CD38 x ICAM-1 Bispecific Antibody Is a Novel Approach for Treating Multiple Myeloma and LymphomASH • December 11-14, 2021; Atlanta, GA